Our mission is to be the leading provider of equity research in healthcare and life sciences

We produce institutional­ quality equity research on small/mid­cap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.

research-clients

14

Research Clients

reports-published

120

Reports published

readers-in-database

10k+

Readers in database

The acquisition of Amal Therapeutics by @Boehringer for up to EUR325m for its therapeutic platform technology, which is just about to enter the clinic, shows how interest in therapeutic vaccines is returning @TransgeneSA @scancellpharma #Mologen

.@MereoBioPharma has established in principle an accelerated approval route for navicixizumab (NAVI) in advanced ovarian cancer with the @US_FDA , paving the way for the programme to be partnered. $MREO up 24% https://t.co/B69tnVxmTE

The strength of @RedxPharma's drug discovery platform is highlighted by the partnering of its pre-clinical pan-Raf inhibitor to @JazzPharma in a deal worth up to $203m in milestones plus royalties. $REDX.L shares up 124%

.@Yourgene_Health well on the way to profitability with FY19 revenues up 45% to £8.9m and operating loss reduced by 44% to £4.8m. With the litigation and debt issues resolved, the company's focus has switched firmly to the opportunities ahead.

Positive feedback & momentum for @NexstimOyj as its 1st US #depression customer, @IslandPsychLI, purchases a second #SmartFocus NBT system for use in the treatment of MDD. $NXTMH / $NXTMS

Following today's trading update from @scancellpharma, read our note entitled "Ground prepared for an important period" at https://t.co/mZuSJRY5Vy

Subscribe to our research

Please sign up here to be added to our distribution database